Compugen Ltd. (CGEN)
Oxford Ledge is still expanding full research coverage of CGEN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Compugen is a clinical-stage cancer immunotherapy company using AI-powered discovery to develop novel therapeutic candidates through internal programs and partnerships.
SEC filings
- 6-K Interim report (foreign private issuer) 2026-05-18
- 20-F Annual report (foreign private issuer) 2026-03-02
- 6-K Interim report (foreign private issuer) 2026-03-02
- 6-K Interim report (foreign private issuer) 2026-02-12
- 6-K Interim report (foreign private issuer) 2025-12-17
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CGEN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CGEN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.